CHI Advisors LLC
- SEC CIK
- 0001791468
- Latest filing
- Nov 13, 2023
Holdings in Q1 2023
Holdings as of Mar 31, 2023, filed May 11, 2023. Long positions only; changes compare share counts with Q4 2022.
- Positions
- 23
- +1 vs. Q4 2022
- Portfolio value
- $376.6M
- +$1.16M (+0.3%) vs. Q4 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ONCROncorus, Inc. | COM | 2,367,436 | $814.6K | 0.2% | 00.0% | Unchanged | History |
| TRDAEntrada Therapeutics, Inc. | COM | 56,374 | $817.4K | 0.2% | +56,374 | New | History |
| SYRSSyros Pharmaceuticals, Inc. | COM NEW | 767,445 | $2.05M | 0.5% | +767,445 | New | History |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 2,339,402 | $2.13M | 0.6% | −45,000−1.9% | Reduced | History |
| Freeline Therapeutics Hldgs35655L107 | SPONSORED ADS | 4,729,419 | $2.15M | 0.6% | −85,000−1.8% | Reduced | – |
| KZRKezar Life Sciences, Inc. | COM | 689,451 | $2.16M | 0.6% | −1,200,000−63.5% | Reduced | History |
| OVIDOvid Therapeutics Inc. | COM | 864,822 | $2.23M | 0.6% | 00.0% | Unchanged | History |
| DTILPrecision Biosciences Inc | COM | 3,469,820 | $2.61M | 0.7% | −80,000−2.3% | Reduced | History |
| KDNYChinook Therapeutics, Inc. | COM | 135,000 | $3.13M | 0.8% | +135,000 | New | History |
| ORTXOrchard Therapeutics plc | SPON ADS NEW | 785,738 | $4.22M | 1.1% | −13,002−1.6% | ReducedConverted for a 1-for-10 split | History |
| RLYBRallybio Corp | COM | 760,543 | $4.34M | 1.2% | +34,434+4.7% | Added | History |
| IMAImageneBio, Inc. | COM | 1,660,872 | $5.73M | 1.5% | +23,500+1.4% | Added | History |
| OMGAOmega Therapeutics, Inc. | COMMON STOCK | 1,055,882 | $6.37M | 1.7% | 00.0% | Unchanged | History |
| INZYInozyme Pharma, Inc. | COM | 1,342,191 | $7.69M | 2.0% | −862,685−39.1% | Reduced | History |
| TSVT2seventy bio, Inc. | COMMON STOCK | 855,000 | $8.72M | 2.3% | +521,748+156.6% | Added | History |
| CMPXCompass Therapeutics, Inc. | COM | 2,829,712 | $9.25M | 2.5% | 00.0% | Unchanged | History |
| KROSKeros Therapeutics, Inc. | COM | 261,059 | $11.1M | 3.0% | +46,000+21.4% | Added | History |
| LRMRLarimar Therapeutics, Inc. | COM | 2,746,265 | $12.4M | 3.3% | −727,101−20.9% | Reduced | History |
| RPTXRepare Therapeutics Inc. | COM | 2,997,939 | $29.5M | 7.8% | +197,813+7.1% | Added | History |
| CGEMCullinan Therapeutics, Inc. | COM | 3,349,460 | $34.3M | 9.1% | +31,916+1.0% | Added | History |
| Vectivbio Hldg AGH9060V101 | ORD SHS | 5,255,484 | $44.7M | 11.9% | −237,409−4.3% | Reduced | – |
| PLRXPliant Therapeutics, Inc. | COM | 3,001,835 | $79.8M | 21.2% | −168,057−5.3% | Reduced | History |
| RXDXPrometheus Biosciences, Inc. | COM | 934,135 | $100.3M | 26.6% | +10,335+1.1% | Added | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| RXDXPrometheus Biosciences, Inc. | COM | – | $108.1K |
Sold out since Q4 2022 (2)
Positions held at the end of Q4 2022 that are gone from this filing.